Corporate Banner
Satellite Banner
Informatics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Optibrium Announces a New Release of StarDrop Introducing MPO Explorer

Published: Tuesday, January 14, 2014
Last Updated: Tuesday, January 14, 2014
Bookmark and Share
The new module, alongside data visualisation enhancements, further extends StarDrop’s capabilities to reduce the time and cost to deliver high quality drug candidates.

Optibrium™, today announced the release of a new version of its StarDrop™ software platform. The latest release introduces MPO Explorer™, which provides innovative new methods to guide ‘strategic’ decisions in research programmes, by helping to identify the key properties and selection criteria with which to select compounds with a high chance of success. The new module, alongside data visualisation enhancements, further extends StarDrop’s capabilities to reduce the time and cost to deliver high quality drug candidates.

MPO Explorer introduces unique (patent pending) methods that guide the development and validation of multi-parameter scoring profiles, tailored to a discovery project’s specific objectives. The resulting scoring profiles can be applied with StarDrop’s Probabilistic Scoring approach for multi-parameter optimisation (MPO), to effectively target novel compounds with a high chance of success. The most important property criteria are also highlighted, focussing experimental resources to generate the key data with which to identify successful compounds. To promote objective decision making, the new module also tests if a specific property criteria in a scoring profile may be artificially distorting the selection of compounds to pursue. If a small change in a criterion would lead to a different decision, this can highlight new avenues for exploration and avoid missed opportunities.

These new capabilities are supported by further enhancements to the core StarDrop application, including new data visualisation features such as 3D scatter and chemical space plots.  In addition, StarDrop’s R-group analysis tool has been extended to perform matched pair analysis, providing insight into the key substitutions in a chemical series that have a significant impact on a compound’s properties.

Dr Matthew Segall, Optibrium’s CEO, commented: “StarDrop now offers our users a comprehensive desktop environment to guide strategic decisions in their drug discovery projects, optimise the use of resources and intuitively target compounds with an improved chance of success. The latest release delivers new technologies that represent the culmination of years of leading edge research and further our goals to improve the efficiency and productivity of our customers’ discovery projects.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,100+ scientific posters on ePosters
  • More than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Optibrium Signs Agreement for Global License of StarDrop
Company has announced that Janssen Research and Development has signed an agreement to license Optibrium’s StarDrop software.
Tuesday, May 24, 2016
BioSolveIT and Optibrium Sign Collaboration Agreement
Partnership will deliver a link between 2D and 3D design on medicinal chemists’ desktops.
Tuesday, October 20, 2015
Optibrium Appoints Head of North American Operations to Support Growing Demand
Appointment marks the opening of new office in Cambridge, MA.
Thursday, September 03, 2015
Optibrium and Certara Collaborate
Collaboration will see integration of Optibrium’s StarDrop and Certera’s D360 platform.
Tuesday, April 21, 2015
Optibrium and ChemAxon Collaborate
Interface between StarDrop and Plexus facilitates seamless access to both software platforms.
Wednesday, April 15, 2015
Optibrium and NextMove Software Announce Technology Collaboration
Automatic application of Matsy method for matched series analysis within StarDrop™ will guide compound optimization in drug discovery.
Friday, January 16, 2015
Optibrium Appoints Director of Computational Chemistry
Appointment of Dr Peter Hunt represents part of further growth across all areas of its business.
Tuesday, April 29, 2014
Optibrium Joins HeCaToS Project and Expands R&D Team
The Hepatic and Cardiac Toxicity Systems project is a major European project with the objective to efficiently investigate the health impact of compounds on the heart and liver.
Tuesday, October 08, 2013
Optibrium Goes from Strength to Strength as Global Customer Base Continues to Grow
Company celebrates growth in all areas of the company as it enters its fourth year of business.
Friday, September 21, 2012
Optibrium and Cresset Announce Technology Collaboration
Technology exchange combines unique methods for design of novel, high quality compounds in drug discovery.
Thursday, January 05, 2012
Optibrium Showcases StarVue at ACS Spring 2010
Offering an Innovative Free Way to Explore Compound Data for Drug Discovery
Thursday, February 18, 2010
Scientific News
Advancing Protein Visualization
Cryo-EM methods can determine structures of small proteins bound to potential drug candidates.
Gene Expression Controls Revealed
Researchers have modelled every atom in a key part of the process for switching on genes, revealing a whole new area for potential drug targets.
Making Genetic Data Easier to Search
Scripps team streamlines biomedical research by making genetic data easier to search.
Monovar Drills Down Into Cancer Genome
Rice, MD Anderson develop program to ID mutations in single cancer cells.
It’s Now Easier To Go With The Flow
Rice University tool simplifies comparison of flow cytometry data for laboratories.
Making Precision Medicine a Reality
Researchers are one step closer to understanding the genetic and biological basis of diseases like cancer, diabetes, Alzheimer’s and rheumatoid arthritis – and identifying new drug targets and therapies.
New Database for Sharing MS Clinical Trial Data
A new database containing nearly 2500 patient records from the placebo arms of nine multiple sclerosis (MS) clinical trials is now available for research by qualified investigators.
‘Precision Prevention’ for Colorectal Cancer
New risk prediction model — not yet ready for clinical use — incorporates genetic, lifestyle and environmental risk factors.
Characterizing Cancerous Genomic Variations
Tested on large tumor genomics database, REVEALER method allows researchers to connect genomics to cell function.
Uncovering Hidden Genomic Alterations that Drive Cancers
Tested on large tumor genomics database, REVEALER method allows researchers to connect genomics to cell function.
Scroll Up
Scroll Down
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,100+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!